MedTrace Logo

An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients

NCT02555709 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2018-10-30

No results posted yet for this study

Summary

This is a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742 will be administered to normal healthy volunteers (NHV) and to moderate to severe psoriatic patients, both in sequential ascending dose panels.

Conditions

Interventions

DRUG

VTP-43742

VTP-43742 administered as an oral capsule once daily

DRUG

Placebo 1

Placebo 1 matching VTP-43742 administered as an oral capsule once daily

DRUG

Placebo 2

Placebo 2 matching VTP-43742 administered as an oral capsule once daily

Sponsors & Collaborators

  • Vitae Pharmaceuticals Inc., an Allergan affiliate

    lead INDUSTRY

Principal Investigators

  • Richard Gregg, MD · Vitae Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02555709 on ClinicalTrials.gov